• licensing agreement

Active Motif Incorporated Licenses Targeted Transposition to Diagenode S.A. Technology

PRNewswire August 1, 2022

CARLSBAD, Calif., Aug. 1, 2022 /PRNewswire/ — Active Motif Incorporated, a company with the vision of bringing┬áepigenetics more deeply into┬áprecision medicine, announced┬áthat┬áit┬áhas┬ánon-exclusively licensed┬áits┬áfoundational patents in┬átransposition for use in┬áCUT&Tag┬áepigenetic assays to Diagenode S.A., a Hologic company (NASDAQ: HOLX). The┬áinnovations underlying these patents allow┬ámechanistic, translational, and clinical researchers to interrogate open chromatin with the goal of gaining an increased understanding of biological processes.┬á Through the licensing arrangement, Diagenode gains access to Active Motif’s patents, which include US9938524, EP2783001, US10689643, US11306307,┬áEP┬á2999784, and other related patent┬áapplications.

Details about Active Motif’s proprietary Cut&Tag-ITÔäó┬átechnology can be found at www.activemotif.com/catalog/1318/cut-tag-it-kit

About Active Motif
Active Motif, Inc. is dedicated to developing, manufacturing and delivering epigenetics-based research tools to analyze nuclear function. Its customers include scientists from academic and government institutions; biotechnology and pharmaceutical companies. Active Motif operates globally through its corporate headquarters in Carlsbad, California and offices in Shanghai China, Tokyo Japan and Waterloo Belgium. Active Motif applies a multi-disciplinary approach to create new and modify existing technologies to meet the current and future needs of life science researchers.

Media Contact: Fritz Eibel, Active Motif Incorporated, Feibel@activemotif.com


SOURCE Active Motif

AAPR aggregates press releases and media statements from around the world to assist our news partners with identifying and creating timely and relevant news.

All of the press releases published on this website are third-party content and AAP was not involved in the creation of it. Read the full terms.